Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CNCR

Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News

About Range Cancer Therapeutics ETF (NASDAQ:CNCR)

Key Stats

Today's Range
$11.87
$12.21
50-Day Range
$27.45
$32.25
52-Week Range
$25.99
$35.82
Volume
2,507 shs
Average Volume
6,668 shs
Market Capitalization
$14.27 million
Assets Under Management
$9.94 million
Dividend Yield
2.40%
Net Expense Ratio
0.79%
Aggregate Rating
Moderate Buy

ETF Overview

The Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.

Range Cancer Therapeutics ETF Expenses

TypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.79%0.57%0.55%0.50%0.52%
Other Expenses0.00%0.30%0.49%0.41%0.53%
Total Expense0.79%0.70%0.71%0.64%0.71%
Fee Waiver0.00%-0.45%-0.51%-0.31%-0.56%
Net Expense0.79%0.61%0.61%0.57%0.59%
Receive CNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter.

CNCR ETF News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.
Range Oncology Therapeutics Index ETF (CNCR)
See More Headlines

CNCR ETF - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF).

Fund Details

Issuer
Exchange Traded Concepts
Fund Name
Range Cancer Therapeutics ETF
Tax Classification
Regulated Investment Company
Current Symbol
NASDAQ:CNCR
Inception Date
10/13/2015
Fund Manager
Denise M. Krisko
Web
N/A
Phone
N/A

Fund Focus

Asset Class
Equity
Benchmark
Range Cancer Therapeutics Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
76

Fund Statistics

Assets Under Management
$9.94 million
Average Daily Volume
$3,212.70
Discount/Premium
0.06%

Administrator, Advisor and Custodian

Administrator
U.S. Bancorp Fund Services, LLC
Advisor
Exchange Traded Concepts, LLC
Custodian
U.S. Bank, N.A.
Distributor
Quasar Distributors, LLC
Transfer Agent
U.S. Bank, N.A.
Trustee
N/A
Lead Market Maker
Jane Street

Options

Optionable
N/A
Short Interest
3,900 shs

Miscellaneous

Beta
1.36
Creation Unit
50,000
Creation Fee
$150.00
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Top 10 CNCR Holdings

CNCR Sector Exposure

CNCR Industry Exposure


This page (NASDAQ:CNCR) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners